S&P 500   3,381.44 (+0.03%)
DOW   27,904.67 (-0.26%)
QQQ   272.85 (+0.36%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
S&P 500   3,381.44 (+0.03%)
DOW   27,904.67 (-0.26%)
QQQ   272.85 (+0.36%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
S&P 500   3,381.44 (+0.03%)
DOW   27,904.67 (-0.26%)
QQQ   272.85 (+0.36%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
S&P 500   3,381.44 (+0.03%)
DOW   27,904.67 (-0.26%)
QQQ   272.85 (+0.36%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
Log in

NASDAQ:VRAYViewray Stock Price, Forecast & News

$3.24
-0.02 (-0.61 %)
(As of 08/13/2020 11:11 AM ET)
Add
Compare
Today's Range
$3.17
Now: $3.24
$3.27
50-Day Range
$1.95
MA: $2.45
$3.53
52-Week Range
$1.11
Now: $3.24
$4.88
Volume12,356 shs
Average Volume2.08 million shs
Market Capitalization$479.34 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Read More
Viewray logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRAY
CUSIPN/A
Phone440-703-3210

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$87.78 million
Book Value$1.47 per share

Profitability

Net Income$-120,200,000.00
Net Margins-166.74%

Miscellaneous

EmployeesN/A
Market Cap$479.34 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$3.24
-0.02 (-0.61 %)
(As of 08/13/2020 11:11 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Viewray (NASDAQ:VRAY) Frequently Asked Questions

How has Viewray's stock price been impacted by COVID-19 (Coronavirus)?

Viewray's stock was trading at $1.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VRAY shares have increased by 91.7% and is now trading at $3.24.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Viewray?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Viewray
.

When is Viewray's next earnings date?

Viewray is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Viewray
.

How were Viewray's earnings last quarter?

Viewray Inc (NASDAQ:VRAY) announced its earnings results on Thursday, July, 30th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.02. The company had revenue of $14.22 million for the quarter, compared to the consensus estimate of $5.81 million. Viewray had a negative return on equity of 63.41% and a negative net margin of 166.74%.
View Viewray's earnings history
.

What price target have analysts set for VRAY?

9 Wall Street analysts have issued 1 year price objectives for Viewray's stock. Their forecasts range from $2.00 to $8.00. On average, they anticipate Viewray's stock price to reach $4.56 in the next year. This suggests a possible upside of 40.8% from the stock's current price.
View analysts' price targets for Viewray
.

Has Viewray been receiving favorable news coverage?

Media stories about VRAY stock have trended extremely negative this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Viewray earned a news impact score of -4.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
View the latest news about Viewray
.

Who are some of Viewray's key competitors?

What other stocks do shareholders of Viewray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Viking Therapeutics (VKTX), AbbVie (ABBV) and Accuray (ARAY).

When did Viewray IPO?

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is Viewray's stock symbol?

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

Who are Viewray's major shareholders?

Viewray's stock is owned by many different institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.62%), Rhenman & Partners Asset Management AB (0.53%), Essex Investment Management Co. LLC (0.34%), Bank of New York Mellon Corp (0.33%), King Luther Capital Management Corp (0.19%) and California Public Employees Retirement System (0.15%). Company insiders that own Viewray stock include International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin.
View institutional ownership trends for Viewray
.

Which major investors are selling Viewray stock?

VRAY stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Ieq Capital LLC, Rhenman & Partners Asset Management AB, King Luther Capital Management Corp, Essex Investment Management Co. LLC, Swiss National Bank, and Arizona State Retirement System.
View insider buying and selling activity for Viewray
.

Which major investors are buying Viewray stock?

VRAY stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., California Public Employees Retirement System, Bank of New York Mellon Corp, UBS Group AG, Hodges Capital Management Inc., New York State Common Retirement Fund, Principal Financial Group Inc., and Virtu Financial LLC. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake, and Shahriar Matin.
View insider buying and selling activity for Viewray
.

How do I buy shares of Viewray?

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Viewray's stock price today?

One share of VRAY stock can currently be purchased for approximately $3.24.

How big of a company is Viewray?

Viewray has a market capitalization of $479.34 million and generates $87.78 million in revenue each year. The company earns $-120,200,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

What is Viewray's official website?

The official website for Viewray is www.viewray.com.

How can I contact Viewray?

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.